7 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 tablet dose with four XTANDI® 40 mg film-coated tablets. With the clinical results we are on track to support product launch post expiry of the enzalutamide substance patent in the respective territories. The nanoenzalutamide tablet formulation was developed in a partnership with the ONConcept® Consortium (Bluepharma, Helm, Welding). Tablet-burden and dysphagia are well-documented challenges for prostate cancer patients, and the development of a nanoformed onceper-day regimen may be preferable for patients in need of reducing their daily pill burden. “We commenced this bioequivalence study as planned and our commercialization partners are excited about our CESS® technology, the IP advantages, the patient, sustainability & cost benefits and hence see significant commercial value in Nanoform’s technologies” said Prof. Edward Haeggström, CEO of Nanoform. The first license and supply agreement (LSA) has now been signed (Germany), while LSAs for several other key markets (e.g. US, Japan, France) are expected to be signed in the coming months. The total value the Nanoenzalutamide project could bring to Nanoform and its ONConcept® partners is EUR 10m+ in potential development milestones up until launch, EUR 25m+ in potential commercial milestones and significant profit share after launch. Nanoform continues to advance its other small and large molecule product kernels and customer projects to clinic. References 1. XTANDI® is a registered trademark of Astellas Pharma Inc. 2. Source: xtandi.com Ecolab Life Sciences announced it has launched an innovative new resin to help achieve cost savings and optimize operations throughout the antibody manufacturing process. Purolite™ AP+50 is an affinity chromatography resin with a 50-micron bead size offering the highest dynamic binding capacity of the AP resin platform while providing excellent durability for monoclonal antibody capture. It also leverages Ecolab’s patented Jetted resin bead manufacturing technology, an innovative approach that enables lot-to-lot consistency and shorter lead times. It is the latest addition to Ecolab’s robust Purolite Resin affinity toolbox which helps biopharmaceutical companies and Contract Development and Manufacturing Organizations solve complex purification challenges. “The ability to effectively improve process economics while maintaining purity is the gold standard of resin purification. As pharmaceutical and biotech companies seek to increase savings and improve business continuity, they are requiring innovative solutions to accelerate and de-risk manufacturing,” said Meeta Gulyani, senior vice president and general manager, Ecolab Bioprocessing. “Our resins are designed to help customers improve their product development platforms and implement next-generation manufacturing processes as well as enhance dual sourcing strategies that can reduce costs and bolster supply chains.” Purolite AP+50 resin joins Ecolab’s full suite of purification resins including the recently launched Purolite DurA Cycle™ A50 for longer lifetimes and Purolite 70 CH1 which targets complex antibody fragments. Together, they support process intensification strategies and cost of goods reduction, which are critical in late-phase, large-scale manufacturing. Ecolab’s newest innovation is being formally introduced at the 2025 BIO International Convention in Boston, Massachusetts from June 16 – 19, 2025. Attendees are invited to learn more about Purolite AP+50 resin at the Ecolab booth (#1971) and via a technical presentation at the BPI Theatre on Tuesday, June 17 at 2:40 p.m. EST. The announcement of Ecolab’s latest resin follows news of the opening of its newest Bioprocessing Applications Lab in King of Prussia, Pennsylvania. The new lab complements its UKbased facility, providing dual continent technical support capabilities, including resin screening and development applications to address growing customer demand around the world. Ecolab Life Sciences launches new bioprocessing purification resin to drive manufacturing productivity NEWS
RkJQdWJsaXNoZXIy MjY2OTA4MA==